FULC Average Annual Return Since 2019
Growth of $10,000.00
Without Dividends Reinvested Into FULC


Also see:
FULC stock yearly return 2020
FULC stock yearly return 2021
FULC stock yearly return 2022
FULC stock yearly return 2023
FULC YTD return
Compare FULC average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 07/19/2019
End date: 04/22/2024
Start price/share: $12.55
End price/share: $7.25
Dividends collected/share: $0.00
Total return: -42.23%
FULC Average Annual Return: -10.88%
Starting investment: $10,000.00
Ending investment: $5,776.47
Years: 4.76


FULC average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ß-thalassemia. The FULC average annual return since 2019 is shown above.

The Average Annual Return on the FULC average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether FULC average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the FULC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree FULC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Fulcrum Therapeutics (FULC) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

FWBI Average Annual Return
GALT Average Annual Return
GANX Average Annual Return
GB Average Annual Return
GBIO Average Annual Return
GCTK Average Annual Return
GEHC Average Annual Return
GENE Average Annual Return
GERN Average Annual Return
GH Average Annual Return
More Healthcare companies »

 

FULC Average Annual Return Since 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.